Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Authors not listed

Vitreous -Retina- Macula Consultants of New York · 2006

Abstract

The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2006). A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. <em>Vitreous -Retina- Macula Consultants of New York</em>. https://clinicaltrials.gov/study/NCT00403156
Vancouver
Anonymous. A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Vitreous -Retina- Macula Consultants of New York. 2006.
BibTeX
@misc{anon2006APhase, title = {A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration}, author = {Anonymous}, journal = {Vitreous -Retina- Macula Consultants of New York}, year = {2006}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings